Table II.
Past treatment use pattern (N = 1,095).a
| Type | Treatment | Patients | Duration | Time of Last Treatment Use (%)b | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | median (IQR), mo | <6 mo | 6–12 mo | 1–2 y | 3–4 y | >4y | ||
| Systemic | Methotrexate | 446 | 40.7 | 12 (5–39.6) | 15.7 | 10.3 | 22.0 | 12.8 | 37.0 |
| Acitretin | 204 | 18.6 | 6 (2–12) | 12.3 | 5.9 | 26.0 | 14.2 | 39.7 | |
| Cyclosporine | 151 | 13.8 | 6 (2–12) | 11.9 | 12.6 | 22.5 | 14.6 | 37.7 | |
| Biologic | Etanercept | 393 | 35.9 | 20.5 (7–36) | 15.8 | 8.7 | 36.1 | 18.8 | 19.3 |
| Adalimumab | 200 | 18.3 | 11 (5–16.8) | 25.5 | 18.0 | 38.5 | 12.5 | 4.5 | |
| Infliximab | 99 | 9.0 | 12 (4–24) | 15.2 | 10.1 | 35.4 | 9.1 | 28.3 | |
| Phototherapy | UVB | 590 | 53.9 | 6 (2–12) | 15.3 | 7.8 | 20.7 | 11.0 | 44.4 |
| PUVA | 148 | 13.5 | 6 (3–24) | 2.7 | 2.0 | 9.5 | 6.8 | 79.1 | |
UVB, ultraviolet B; PUVA, oral psoralen plus ultraviolet A
a
The number of treatments totaled n = 2,231 since the N = 1,095 patients may each have received one or more past treatment.
b
Percentages may not total 100% due to unknown/missing data, which did not exceed 2.3%.